Non-Small Cell Lung Cancer Clinical Trials 2023
Non Small Cell Lung Cancer studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect non small cell lung cancer clinical trial in 2023.
Arm Afor Non-Small Cell Lung Cancer
1/ Vaccine With Montanide Adjuvantfor Non-Small Cell Lung Cancer
Pembrolizumab/vibostolimabfor Non-Small Cell Lung Cancer
SGN-PDL1Vfor Esophageal Cancer
FWD1509 MsOHfor Non-Small Cell Lung Cancer
Amivantamabfor Non-Small Cell Lung Cancer
Durvalumab + SoC Chemotherapyfor Non-Small Cell Lung Cancer
Nivolumabfor Non-Small Cell Lung Cancer
RO6958688for Non-Small Cell Lung Cancer
CC-486for Non-Small Cell Lung Cancer
What Are Non-Small Cell Lung Cancer Clinical Trials?
In the United States, an estimated 236,740 adults are diagnosed with non-small cell lung cancer each year. Malignant (cancer) cells develop in the lung tissues as a result of non-small cell lung cancer. It comes in various forms, but the primary risk factor for non-small cell lung cancer is smoking. Men have an 18% 5-year survival rate, while women have a 25% 5-year survival rate. NSCLC has a 26% 5-year survival rate compared to a 7% five years for small-cell lung cancer. It is crucial to remember that survival statistics vary depending on a number of variables, including the stage of the disease and its subtype.
Why is Non-Small Cell Lung Cancer Being Studied Through Clinical Trials?
NSCLC is responsible for around 80–85% of lung cancer cases. The kinds of NSCLC, which originate from many lung cells, are included because they are often treated similarly. Scientists are always looking for better ways to cure its different types via non-Small Cell Lung Cancer Clinical Trials.
Adenocarcinoma often develops in the outer regions of the lung and can be diagnosed quite early. Previously known as bronchioloalveolar carcinoma, adenocarcinoma in situ is associated with an improved prognosis than other forms of lung cancer. Any area of the lung can develop large cell carcinoma. It frequently multiplies and spreads, which might make treatment more challenging. Big cell neuroendocrine carcinoma, a subtype of large cell carcinoma, is a swiftly progressing malignancy that greatly resembles small cell lung cancer.
Cancer due to squamous cells frequently occur in the center of the lungs, close to a major airway, and are frequently associated with a history of tobacco use (smoking).
What Are The Types of Treatments Available For Non-Small Cell Lung Cancer?
Surgery for Non-Small Cell Lung Cancer is one kind of treatment for the disease. Non-Small Cell Lung Cancer with Radiofrequency Ablation (RFA). For non-small cell lung cancer, radiation therapy. Radiation therapy is typically the preferred option for patients who cannot get chemotherapy. Lung tumor symptoms may also be treated locally with stent implantation, PDT, laser therapy, or other approaches. Most people with non-small cell lung cancer are not cured by existing therapy. Participating in one of the several clinical studies being conducted to enhance therapy should be considered if lung cancer is discovered.
What Are Some Recent Breakthrough Clinical Trials For Non-Small Cell Lung Cancer?
2020: Vaccine Treatment for Advanced Non-Small Cell Lung Cancer – The effectiveness of administering the genetically modified Hyper Acute-Lung cancer vaccine to non-small cell lung cancer patients will be evaluated in this two-phase trial. It will determine the recommended vaccination dosage and look at possible side effects and therapeutic advantages. It is believed that the immunological reaction to the foreign material would prompt the immune system to attack the patient's own cancer cells, which have proteins comparable to those in the foreign substance but lack this sugar pattern. As a result, the tumor should either remain stable or begin to shrink.
2020: PF-00299804 in Stage IIIB or Stage IV Not Responding to Standard Therapy for Advanced or Metastatic Cancer - By inhibiting some of the growth-promoting enzymes, PF-00299804 may be able to halt the development of tumor cells. The effectiveness of PF-00299804 in treating those with advanced non-small cell lung cancer is still unknown compared to a placebo. In this randomized phase III trial, PF-00299804 is being tested to see how it treats patients with stage IV non-small cell lung cancer or stage IIIB who have not responded to usual treatment for metastatic or advanced cancer. The study will compare PF-00299804's effectiveness to that of a placebo.
Who Are Some of the Key Research Institutions Conducting Non-Small Cell Lung Cancer Clinical Trial Research?
Abramson Cancer Center - A diagnosis of non-small cell lung cancer is seldom simple. However, you don't have to go through it alone. They have years of expertise guiding patients through this diagnosis because of their staff of lung cancer specialists. By using medicines based on your DNA and nurse navigators who assist you in overcoming obstacles, researchers at the Abramson Cancer Center make all of their non-Small cell lung cancer clinical trials count.
National Cancer Institute - The National Cancer Institute (NCI) is the top governmental organization for cancer education and research. NCI is steadfastly devoted to the fundamental principles of justice, diversity, and inclusion that enable every employee to realize their potential and fully advance the institute's fight against cancer.